argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in ...
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of ...
只需一年两针，罗氏重磅抗体疗法获FDA批准
在中国，ocrelizumab（奥瑞利珠单抗，静脉注射剂型）的上市申请已经于2023年7月获得NMPA受理。该静脉注射剂型产品同样每年只需输注两次，有望显著改善多发性硬化患者的依从性。
首批！只需一年两针，罗氏重磅抗体疗法获FDA批准
今日，罗氏（Roche）宣布美国FDA已批准Ocrevus Zunovo（ocrelizumab & hyaluronidase）皮下制剂用于治疗复发性多发性硬化（RMS）和原发性进展型多发性硬化（PPMS）。之前公布的临床结果显示，Ocrevus ...
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer ...
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said Thursday that the U.S. Food and Drug Administration has approved Tecentriq Hybreza (atezolizumab and hyaluronidase- ...